Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy

BACKGROUND: The majority of urothelial cancers (UC) harbor alterations in retinoblastoma (Rb) pathway genes that can lead to loss of Rb tumour suppressor function. Palbociclib is an oral, selective inhibitor of CDK 4/6 that restores Rb function and promotes cell cycle arrest. METHODS: In this phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Rose, Tracy L., Chism, David D., Alva, Ajjai S., Deal, Allison M., Maygarden, Susan J., Whang, Young E., Kardos, Jordan, Drier, Anthony, Basch, Ethan, Godley, Paul A., Dunn, Mary W., Kim, William Y., Milowsky, Matthew I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189143/
https://www.ncbi.nlm.nih.gov/pubmed/30293995
http://dx.doi.org/10.1038/s41416-018-0229-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189143/
https://www.ncbi.nlm.nih.gov/pubmed/30293995
http://dx.doi.org/10.1038/s41416-018-0229-0

Ejemplares similares